Cancer Research Network in West of England: SWAG SSG Head and Neck Cancer Meeting
This report presents insights from the Clinical Research Network in West of England focusing on cancer research objectives, recruitment targets, and studies conducted in the region. It highlights the progress made, challenges faced, and initiatives taken to enhance cancer research and patient outcomes in the area.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Clinical Research Network West of England SWAG SSG Head and Neck Cancer Meeting Tuesday 13th March Research Report
Clinical Research Network & Cancer Services West ofEngland SWAG - Somerset Wiltshire Avon & Gloucestershire South West Children s Cancer & Leukaemia Research Network
NIHR CRN Objectives for cancer 2017-18 Number of LCRNs achieving on-target recruitment into at least 8 of the 13 Cancer subspecialties, where "on-target" means either improving recruitment by 10% from 2016/17 or meeting the following recruitment targets per 100,000 population served: a) Brain & CNS: 0.2; b) Breast: 8; c) Colorectal: 3; d) Paediatrics: 3; e) Gynae: 3; f) Head & Neck: 1; g) Haematology: 7; h) Lung: 4; i) Sarcoma: 0.1; j) Skin: 0.2; k) Supportive & Palliative Care and Psychosocial Oncology & Survivorship: 3; l) Upper GI: 3; m) Urology: 8.
NIHR CRN High Level Objectives 2017-18 Increase number of participants into NIHR CRN portfolio studies 650,000 in England 21,905 in West of England Increase the number of studies that deliver to time and target Target 80% Increase number of commercial studies delivered through network Reduce NHS study set up times Reduce time taken to recruit first participant
West of England recruitment to Cancer per 100,000 population by subspecialty 2017-18 (Apr-Feb) against YTD target 14 12 10 8 6 4 2 0 Brain and CNS Breast Colorectal Paediatrics Gynaecological Haematology Head and Neck Lung Sarcoma Skin Palliative Care, Psychosocial & Survivorship Upper GI Urology and Lymphoma 2017-18 recruitment per 100,000 population 2017-18 YTD target 2017-18 target
Recruitment to Head and Neck cancer studies and number of studies by LCRN YTD (Apr - Feb) 2017-18 400 365 355 350 326 310 300 268 256 250 219 203 200 179 178 150 131 107 100 79 77 50 34 17 14 13 11 11 10 10 8 8 8 8 7 6 6 4 0 Yorkshire and Humber West Midlands North West Coast Greater Manchester South London Wessex West of England Eastern Kent, Surrey and Sussex North Thames North East and North Cumbria North West London East South West Peninsula Thames Valley and South Midlands Midlands 2017-18 YTD recruitment Number of studies
Recruitment to Head and Neck Cancer studies by Partner Organisation 2017/18 (Apr - Feb) 160 144 140 120 100 80 60 51 40 24 20 0 UNIVERSITY HOSPITALS BRISTOL ROYAL UNITED HOSPITALS BATH GLOUCESTERSHIRE HOSPITALS
2016/17 Recruitment to Head and Neck as % overall Cancer Incidence Recruitment to Head and Neck studies as a % of Cancer Incidence by LCRN 2.50% 2.00% 1.50% 1.00% 0.50% 0.00% West of England South London Greater Manchester North West Coast North West London Wessex Yorkshire and Humber West Midlands Eastern Kent, Surrey and Sussex North Thames North East and North Cumbria South West Peninsula East Thames Valley and South Midlands Midlands Recruitment to Head and Neck studies as a % of Cancer Incidence
Open studies Head and Neck Portfolio ID Project Title Site Gloucestershire Hospitals NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust A randomised placebo- controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab - NIMRAD Trust DARS: a phase III randomised multicentre study of dysphagia optimized intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (s-IMRT) in head and neck cancer Trust Gloucestershire Hospitals NHS Foundation Trust Royal United Hospitals Bath NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust BRAG rating Planned end date Recruited Target PI Candish, Dr Charlie PI email Charlie.Candish@glos. nhs.uk -35.15% 31/05/2018 7 12 IoN Is ablative radio-iodine necessary for low risk differentiated thyroid cancer patients Beasley, Dr Matthew matthew.beasley@uh bristol.nhs.uk 10876 150.59% 18/11/2014 38 10 Gloucestershire Hospitals NHS Foundation Trust Grant, Dr Warren warren.grant@glos.nh s.uk 5.47% 09/04/2018 4 4 University Hospitals Bristol NHS Foundation Hoda.Booz@UHBristol. nhs.uk 16203 Booz, Dr Hoda Cook, Dr Audrey 19.74% 01/07/2020 15 19 Gloucestershire Hospitals NHS Foundation Trust Royal United Hospitals Bath NHS Foundation Trust Audrey.Cook@glos.nhs .uk 4.87% 19/05/2018 7 8 De Winton, Dr Emma emma.dewinton@nhs. net 105.80% 30/11/2022 5 4 University Hospitals Bristol NHS Foundation Beasley, Dr Matthew Hall, Mr Charles matthew.beasley@uh bristol.nhs.uk 19934 -17.81% 31/05/2018 8 12 -53.32% 04/09/2018 0 10 De Winton, Dr Emma emma.dewinton@nhs. net 30.33% 04/09/2018 43 50 Head & Neck 5000 Follow Up Study Thomas, Prof Steven Steve.Thomas@uhbris tol.nhs.uk 32797 105.89% 04/09/2018 156 90
Open studies Head and Neck BRAG rating Planned end date Recruited Target Portfolio ID Project Title A Phase II/III trial of risk- stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)- positive oropharyngeal cancer Site PI PI email Royal United Hospitals Bath NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust De Winton, Dr Emma emma.dewinton@n hs.net 21.03% 20/02/2019 5 6 Beasley, Dr Matthew matthew.beasley@ uhbristol.nhs.uk 18645 -26.72% 20/02/2019 7 18 Evaluation of centralisation in head and neck cancer Thomas, Prof Steven Steve.Thomas@uhb ristol.nhs.uk 9894 214.07% 31/12/2020 398 140 Hoda.Booz@UHBris tol.nhs.uk 18621 CompARE Trial Booz, Dr Hoda -1.98% 01/04/2022 8 35 Beasley, Dr Matthew matthew.beasley@ uhbristol.nhs.uk 19937 SEL-I-METRY 32.81% 30/09/2019 2 4 Assessment of Quality of Life Tools in Medullary Thyroid Cancer (QaLM) Beasley, Dr Matthew matthew.beasley@ uhbristol.nhs.uk 20272 -77.35% 01/10/2017 6 10
Studies in set up Portfolio ID Project Title Site A Randomised Trial of Post Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck TROG 08.09 ANZMTG 01.09 30658 University Hospitals Bristol
Contacts Research Delivery Manager david.rea@nihr.ac.uk Cancer portfolio facilitator jessica.bartlett@nihr.ac.uk Head and Neck research lead steve.thomas@bristol.ac.uk
